Drugs / JSKN021
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07617727 | May 2026 → Oct 2028 expected | cancer | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-04-30 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Results 康宁杰瑞两项双靶点ADC临床前研究数据在2025年AACR年会公布 alphamabonc.com ↗
临床前研究表明，JSKN021具有优异的稳定性，其双毒素载荷设计可有效应对肿瘤异质性，肿瘤抑制效果显著优于单载荷ADC，具有广阔的临床开发前景。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-04-30 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 康宁杰瑞两项双靶点ADC临床前研究数据在2025年AACR年会公布 alphamabonc.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JSKN021 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07617727 ↗ |
| Route | Intravenous | “administered intravenously” NCT07617727 ↗ |